Abstract
Background: DuoResp Spiromax is an inhaled corticosteroid (ICS)/long-acting β2-agonist fixed-dose combination inhaler, designed to reduce common inhaler errors and enhance usability (reliable dosing and good lung deposition) for patients (pts) with asthma/COPD.
Aims/Objectives: To evaluate the non-inferiority of DuoResp after changing from Symbicort, vs staying on Symbicort (pts achieving disease control [based on Risk Domain Control, RDC, algorithm]; exacerbation rate; short-acting β2-agonists (SABA) use; and treatment stability [achieved RDC; no treatment boost]).
Methods: Asthma/COPD pts who changed from Symbicort to DuoResp were matched (3:1) with pts staying on Symbicort. Data were from the Optimum Patient Care Research Database and Clinical Practice Research Datalink. To achieve RDC, pts must not have had respiratory related hospitalization, accident/emergency attendance, exacerbations, and oral CS or antibiotic courses.
Results: Compared with 1091 pts (asthma 743; COPD 348) staying on Symbicort, 385 matched pts (asthma 253; COPD 132) who changed to DuoResp had non-inferiority in RDC (adjusted difference +6.6% [95% CI, -0.3–13.5]). In asthma pts, DuoResp (vs Symbicort) resulted in fewer exacerbations (adjusted rate ratio [RR] 0.76; p=0.044); lower odds of being in a high SABA dose category (OR 0.71; p=0.034); used fewer SABA inhalers (RR 0.92; p=0.019) and higher odds of achieving treatment stability (adjusted odds ratio 1.44; p=0.037). No significant differences were found in COPD pts.
Conclusions: In real-life asthma/COPD patients, DuoResp was non-inferior (in RDC) to Symbicort. In asthma pts, DuoResp was associated with better health outcomes.
Aims/Objectives: To evaluate the non-inferiority of DuoResp after changing from Symbicort, vs staying on Symbicort (pts achieving disease control [based on Risk Domain Control, RDC, algorithm]; exacerbation rate; short-acting β2-agonists (SABA) use; and treatment stability [achieved RDC; no treatment boost]).
Methods: Asthma/COPD pts who changed from Symbicort to DuoResp were matched (3:1) with pts staying on Symbicort. Data were from the Optimum Patient Care Research Database and Clinical Practice Research Datalink. To achieve RDC, pts must not have had respiratory related hospitalization, accident/emergency attendance, exacerbations, and oral CS or antibiotic courses.
Results: Compared with 1091 pts (asthma 743; COPD 348) staying on Symbicort, 385 matched pts (asthma 253; COPD 132) who changed to DuoResp had non-inferiority in RDC (adjusted difference +6.6% [95% CI, -0.3–13.5]). In asthma pts, DuoResp (vs Symbicort) resulted in fewer exacerbations (adjusted rate ratio [RR] 0.76; p=0.044); lower odds of being in a high SABA dose category (OR 0.71; p=0.034); used fewer SABA inhalers (RR 0.92; p=0.019) and higher odds of achieving treatment stability (adjusted odds ratio 1.44; p=0.037). No significant differences were found in COPD pts.
Conclusions: In real-life asthma/COPD patients, DuoResp was non-inferior (in RDC) to Symbicort. In asthma pts, DuoResp was associated with better health outcomes.
| Original language | English |
|---|---|
| Number of pages | 1 |
| Journal | European Respiratory Journal |
| Volume | 50 |
| DOIs | |
| Publication status | Published - 1-Sept-2017 |
| Event | European-Respiratory-Society (ERS) International Congress - Milan, Italy Duration: 9-Sept-2017 → 13-Sept-2017 http://erscongress.org/home-2014.html |
Keywords
- asthma
- copd